Faecal Microbiota Transplantation in the UK: How Our Manufacturer (TML.science) Sets the Gold Standard in Donor Screening

Over the past decade, Faecal Microbiota Transplantation (FMT) has emerged as one of the most promising therapies for restoring gut health, especially in patients suffering from recurrent Clostridioides difficile infections (rCDI) and other microbiome-associated conditions. While its potential continues to expand across the fields of gastroenterology, neurology, immunology, and metabolic health, questions surrounding safety and regulatory compliance have become central to its adoption.

In the United Kingdom, FMT is now regulated as a medicinal product by the Medicines and Healthcare Regulatory Agency (MHRA), requiring manufacturers to meet stringent GMP (Good Manufacturing Practice) standards and obtain relevant licences for production and distribution. Within this regulated landscape, TML.science has established itself as a leader in safe, high-quality FMT manufacturing, distinguished by a comprehensive donor screening programme designed to meet or exceed the key national and international guidelines.

A Regulated and Evolving Industry

In 2018, the MHRA classified FMT as a medicine, a pivotal step that raised the bar for how FMT products must be produced and delivered in the UK. Since then, any organisation involved in manufacturing or supplying FMT must comply with strict safety, traceability, and quality control procedures.

TML.science based in the UK, responded by overhauling its manufacturing practices to align with these evolving standards. With its Manufacturing Specials Licence granted in 2021 and its Marketing Authorisation (MIA) Licence granted in 2024, TML.science stands at the forefront of GMP-compliant FMT manufacturing in Europe.

The Importance of Robust Donor Screening

The cornerstone of any safe and effective FMT programme is the donor screening process. At TML.science, this is not a mere formality, it is a scientifically validated, protocol-driven, multi-stage process designed to ensure the highest level of safety and efficacy for every batch produced.

Here’s what makes TML.science’s screening process stand out:

1. Comprehensive Medical History Assessment

Potential donors undergo a detailed pre-screening interview and lifestyle evaluation, covering:

• Antibiotic usage history
• Travel and risk behaviour
• Family history of autoimmune or metabolic disorders
• Gastrointestinal symptoms or chronic illnesses

2. Advanced Blood and Stool Testing

Donors are screened every 30- and 90-days using ISO-accredited/GMP certified laboratories, undergoing a wide range of pathogen and biomarker testing. These include:

• Blood tests for HIV, Hepatitis A/B/C/E, Syphilis, CMV, EBV, HTLV, and more
• Stool tests for C. difficile, Norovirus, Salmonella, Shigella, Campylobacter, E. coli O157, and parasitic infections and more 
• Stool Test for Covid-19 RNA 

 3. H. pylori Protocol

Uniquely, TML.science also includes H. pylori antibody screening in blood, and where needed, antigen testing in stool to assess active infection status. This two-tiered approach balances patient safety with an evidence-based interpretation of donor suitability.

4. Regular Monitoring & Quarantine

Even after donation, samples are held in quarantine until a follow-up screening confirms the donor remains free of communicable diseases. This additional safeguard ensures that no material is released without post-collection clearance, maintaining full traceability and risk mitigation.

5. Customised Screening Upon Medical Professional Request

TML.science also supports personalised donor screening based on specific clinical needs. If a licensed medical professional or treating physician requests additional testing to tailor FMT to a patient’s condition, TML.science can accommodate these requests.

Beyond Testing: Quality Systems & Governance

TML.science operates under Quality Management system driven systems (Standard Operating Procedures) that govern not only donor screening, but also product release, deviation handling, complaint management, and batch traceability. These procedures are audited internally and externally to meet the expectations of both the MHRA and international partners.

Global Reach, Local Integrity

With international interest growing particularly from clinics and hospitals in the Bahamas, Germany, Slovakia, and beyond TML.science’s commitment to high-grade, transport-stable FMT formulations and safe, screened donor material is setting a new standard for the industry.

Whether it’s through freeze-drying innovations, customised patient formulations, or third-country exports, TML.science continues to support the global expansion of microbiome-based therapies with quality and safety as its foundation.

Final Thoughts

As the science behind FMT progresses, the UK’s role as a regulated manufacturing hub becomes increasingly critical. TML.science not only meets these regulations, it exceeds them, offering clinics and hospitals access to FMT products manufactured to the highest quality and safety standards.